Overview

Low Dose Thymoglobin in Renal Transplant Patients

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:
0

Participant gender:
All

Summary

This is a planned single center prospective randomized study evaluating the safety and efficacy of low dose thymoglobulin as induction agent in renal transplant recipients. Inclusion criteria will be adult renal transplant recipients who are not sensitized against their potential donors. The patients who agree to participate in the study will be randomly assigned to either thymoglobulin at 1.25mg/kg x 3 doses or 0.75mg/kg x 3 doses. There will be 86 sealed envelopes to perform the randomization process. 43 envelopes with 1.25mg/kg dosing and the other 43 envelopes with 0.75mg/kg dosing. The investigators will sequentially choose the sealed envelopes at the time of the patient randomization process. All patients will be started on our standard immunosupression regimen of prograf/cellcept and a fast steroid taper. Data will be obtained from every patient for up to one year post-transplant.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Lahey Clinic

Collaborator:

Brigham and Women's Hospital

Treatments:

Antilymphocyte Serum
Thymoglobulin

Criteria

Inclusion Criteria:

Potential Adult Renal Transplant Patients -

Exclusion Criteria:

Sensitized Renal Transplant Patients

-